Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 4
1992 1
1993 1
1994 3
1995 4
1996 2
1997 2
1998 4
1999 2
2000 5
2001 3
2002 6
2005 2
2006 1
2007 3
2008 2
2010 2
2011 3
2012 1
2014 5
2015 2
2017 2
2018 1
2019 1
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Results by year
Filters applied: . Clear all
Page 1
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. Among authors: flaherty le. J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880964 Free PMC article. Clinical Trial.
Biochemotherapy of melanoma.
Flaherty LE, Gadgeel SM. Flaherty LE, et al. Semin Oncol. 2002 Oct;29(5):446-55. doi: 10.1053/sonc.2002.35239. Semin Oncol. 2002. PMID: 12407509 Review.
Biochemotherapy for melanoma.
Philip PA, Flaherty LE. Philip PA, et al. Among authors: flaherty le. Curr Oncol Rep. 2000 Jul;2(4):314-21. doi: 10.1007/s11912-000-0024-x. Curr Oncol Rep. 2000. PMID: 11122859 Review.
Adjuvant high-dose interferon revisited.
Sondak VK, Flaherty LE. Sondak VK, et al. Among authors: flaherty le. Cancer J. 2000 May-Jun;6(3):132-4. Cancer J. 2000. PMID: 10882326 Review. No abstract available.
ACCO: ASCO core curriculum outline.
Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Schapira L, Sparano J; American Society of Clinical Oncology. Muss HB, et al. Among authors: flaherty le. J Clin Oncol. 2005 Mar 20;23(9):2049-77. doi: 10.1200/JCO.2005.99.008. Epub 2005 Feb 22. J Clin Oncol. 2005. PMID: 15728218 No abstract available.
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. Samlowski WE, et al. Among authors: flaherty le. Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10. Cancer Med. 2017. PMID: 28994212 Free PMC article. Clinical Trial.
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. Among authors: flaherty le. J Immunother Cancer. 2021 May;9(5):e002535. doi: 10.1136/jitc-2021-002535. J Immunother Cancer. 2021. PMID: 33963015 Free PMC article. Clinical Trial.
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. Budd GT, et al. Among authors: flaherty le. J Clin Oncol. 2015 Jan 1;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. Epub 2014 Nov 24. J Clin Oncol. 2015. PMID: 25422488 Free PMC article. Clinical Trial.
61 results